Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Commentary. In Praise of Studies That Use More Than One Generic Preference-Based Measure.

Feeny D, Furlong W, Torrance GW.

Int J Technol Assess Health Care. 2019;35(4):257-262. doi: 10.1017/S0266462319000412. Epub 2019 Jul 12.

PMID:
31296277
2.

What were they thinking when providing preference measurements for generic health states? The evidence for HUI3.

Feeny D, Furlong W, Torrance GW.

Health Qual Life Outcomes. 2018 Aug 15;16(1):166. doi: 10.1186/s12955-018-0993-9.

3.

BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis.

Bellamy N, Bell MJ, Goldsmith CH, Lee S, Maschio M, Raynauld JP, Torrance GW, Tugwell P.

J Clin Epidemiol. 2010 May;63(5):566-74. doi: 10.1016/j.jclinepi.2009.07.011. Epub 2009 Nov 6.

PMID:
19896801
4.

Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?

Oldridge N, Furlong W, Perkins A, Feeny D, Torrance GW.

Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):608-15. doi: 10.1097/HJR.0b013e328304fec1.

PMID:
18800005
5.

Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.

Marshall DA, Douglas PR, Drummond MF, Torrance GW, Macleod S, Manti O, Cheruvu L, Corvari R.

Pharmacoeconomics. 2008;26(6):477-95. Review.

PMID:
18489199
6.

A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.

Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW.

J Rheumatol. 2007 Mar;34(3):534-42.

PMID:
17343301
7.

BLISS index for analyzing knee osteoarthritis trials data.

Bellamy N, Bell MJ, Pericak D, Goldsmith CH, Torrance GW, Raynauld JP, Walker V, Tugwell P, Polisson R.

J Clin Epidemiol. 2007 Feb;60(2):124-32. Epub 2006 Aug 30.

PMID:
17208118
8.

Utility measurement in healthcare: the things I never got to.

Torrance GW.

Pharmacoeconomics. 2006;24(11):1069-78. Review.

PMID:
17067192
9.

Measuring quality of life: the development and initial validation of the patient-reported erectile function assessment instrument.

Torrance GW, Keresteci MA, Casey R, Ryan NC, Tarride JE.

Int J Technol Assess Health Care. 2006 Summer;22(3):372-8.

PMID:
16984066
10.

The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function.

Casey R, Tarride JE, Keresteci MA, Torrance GW.

Can J Urol. 2006 Apr;13(2):3016-25; discussion 3026.

PMID:
16672112
11.

Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee.

Marshall DA, Strauss ME, Pericak D, Buitendyk M, Codding C, Torrance GW.

Am J Manag Care. 2006 Apr;12(4):205-14.

12.

Letter to the Editor: Reply to the letter by Max I. Hamburger.

Raynauld JP, Goldsmith CH, Torrance GW; Steering Committee And Clinical Investigators Of The Canadian Knee Oa Study Group.

Osteoarthritis Cartilage. 2005 Nov;13(11):1037-8; author reply 1039-40. Epub 2005 Sep 19. No abstract available.

13.

Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis.

Raynauld JP, Goldsmith CH, Bellamy N, Torrance GW, Polisson R, Belovich D, Pericak D, Tugwell P.

Osteoarthritis Cartilage. 2005 Feb;13(2):111-9.

14.

The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R.

Osteoarthritis Cartilage. 2005 Feb;13(2):104-10.

15.

Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R.

Ann Rheum Dis. 2005 Jun;64(6):881-5. Epub 2004 Nov 25.

16.

Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function.

Torrance GW, Keresteci MA, Casey RW, Rosner AJ, Ryan N, Breton MC.

Qual Life Res. 2004 Mar;13(2):349-59.

PMID:
15085907
17.

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.

Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N.

Rheumatology (Oxford). 2004 Jun;43(6):712-8. Epub 2004 Mar 23.

PMID:
15039494
18.

Switching therapy in health economics trials: confronting the confusion.

Torrance GW, Drummond MF, Walker V.

Med Decis Making. 2003 Jul-Aug;23(4):335-40.

PMID:
12926583
19.

Willingness to pay for what? A note on alternative definitions of health care program benefits for contingent valuation studies.

Currie GR, Donaldson C, O'Bbrien BJ, Stoddart GL, Torrance GW, Drummond MF.

Med Decis Making. 2002 Nov-Dec;22(6):493-7.

PMID:
12458979
20.

The development and use of quality-of-life measures to evaluate health outcomes in Japan.

Fukuhara S, Ikegami N, Torrance GW, Nishimura S, Drummond M, Schubert F.

Pharmacoeconomics. 2002;20 Suppl 2:17-23. Review.

PMID:
12238945
21.

Information barriers to the implementation of economic evaluations in Japan.

Nishimura S, Torrance GW, Ikegami N, Fukuhara S, Drummond M, Schubert F.

Pharmacoeconomics. 2002;20 Suppl 2:9-15. Review.

PMID:
12238944
22.

Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Ikegami N, Drummond M, Fukuhara S, Nishimura S, Torrance GW, Schubert F.

Pharmacoeconomics. 2002;20 Suppl 2:1-7. Review.

PMID:
12238943
23.

Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis.

Feeny D, Townsend M, Furlong W, Tomkins DJ, Robinson GE, Torrance GW, Mohide PT, Wang Q.

Genet Test. 2002 Spring;6(1):39-46.

PMID:
12180075
24.

A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results.

Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, Schultz M, Tugwell P; Canadian Knee OA Study Group.

Osteoarthritis Cartilage. 2002 Jul;10(7):518-27.

25.

A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results.

Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N; Canadian Knee OA Study Group.

Osteoarthritis Cartilage. 2002 Jul;10(7):506-17.

26.

The burden of illness of severe nausea and vomiting of pregnancy in the United States.

Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, Torrance GW.

Am J Obstet Gynecol. 2002 May;186(5 Suppl Understanding):S220-7.

PMID:
12011890
27.

Looking back and looking forward: viewed through the eyes of George Torrance.

Torrance GW.

Med Decis Making. 2002 Mar-Apr;22(2):178-81. No abstract available.

PMID:
11958500
28.

Health utility estimation.

Torrance GW, Furlong W, Feeny D.

Expert Rev Pharmacoecon Outcomes Res. 2002 Apr;2(2):99-108. doi: 10.1586/14737167.2.2.99.

PMID:
19807322
29.

Cost-effectiveness of Apligraf in the treatment of venous leg ulcers.

Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P.

Ostomy Wound Manage. 2001 Aug;47(8):36-46.

PMID:
11890002
30.

Multiattribute and single-attribute utility functions for the health utilities index mark 3 system.

Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M.

Med Care. 2002 Feb;40(2):113-28.

PMID:
11802084
31.

The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies.

Furlong WJ, Feeny DH, Torrance GW, Barr RD.

Ann Med. 2001 Jul;33(5):375-84. Review.

PMID:
11491197
32.

Visual analog scales: do they have a role in the measurement of preferences for health states?

Torrance GW, Feeny D, Furlong W.

Med Decis Making. 2001 Jul-Aug;21(4):329-34.

PMID:
11475389
33.

What should be reported in a methods section on utility assessment?

Stalmeier PF, Goldstein MK, Holmes AM, Lenert L, Miyamoto J, Stiggelbout AM, Torrance GW, Tsevat J.

Med Decis Making. 2001 May-Jun;21(3):200-7.

PMID:
11386627
34.

Development and testing of a utility measure for major, unipolar depression (McSad).

Bennett KJ, Torrance GW, Boyle MH, Guscott R, Moran LA.

Qual Life Res. 2000 Feb;9(1):109-20.

PMID:
10981211
35.

Cost-utility analysis in depression: the McSad utility measure for depression health states.

Bennett KJ, Torrance GW, Boyle MH, Guscott R.

Psychiatr Serv. 2000 Sep;51(9):1171-6.

PMID:
10970923
36.

Cost and health related quality of life consequences of multiple sclerosis.

Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L.

Mult Scler. 2000 Apr;6(2):91-8.

PMID:
10773854
37.

The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Glennie JL, Torrance GW, Baladi JF, Berka C, Hubbard E, Menon D, Otten N, Rivière M.

Pharmacoeconomics. 1999 May;15(5):459-68.

PMID:
10537963
38.

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.

Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ, Willison DJ.

Pharmacoeconomics. 1998 Nov;14(5):559-73.

PMID:
10344918
39.

Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care.

O'Brien BJ, Goeree R, Gafni A, Torrance GW, Pauly MV, Erder H, Rusthoven J, Weeks J, Cahill M, LaMont B.

Med Care. 1998 Mar;36(3):370-84.

PMID:
9520961
40.

Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.

Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr, Torrance GW.

Health Econ. 1997 Sep-Oct;6(5):505-10. No abstract available.

PMID:
9353651
41.

Health state utilities in knee replacement surgery: the development and evaluation of McKnee.

Bennett KJ, Torrance GW, Moran LA, Smith F, Goldsmith CH.

J Rheumatol. 1997 Sep;24(9):1796-805.

PMID:
9292806
42.

Preferences for health outcomes and cost-utility analysis.

Torrance GW.

Am J Manag Care. 1997 May;3 Suppl:S8-20.

43.

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.

Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR.

Pharmacoeconomics. 1997 Feb;11(2):159-68. Review.

PMID:
10172935
44.

Canada's new guidelines for the economic evaluation of pharmaceuticals.

Menon D, Schubert F, Torrance GW.

Med Care. 1996 Dec;34(12 Suppl):DS77-86. No abstract available.

PMID:
8969316
45.

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2.

Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q.

Med Care. 1996 Jul;34(7):702-22.

PMID:
8676608
46.

Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, Tugwell P, Konchak R, Hubbard E, Firestone T.

Pharmacoeconomics. 1996 Jun;9(6):535-59.

PMID:
10160481
47.

Reliability of the Health Utilities Index--Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire.

Boyle MH, Furlong W, Feeny D, Torrance GW, Hatcher J.

Qual Life Res. 1995 Jun;4(3):249-57.

PMID:
7613535
48.

Multi-attribute preference functions. Health Utilities Index.

Torrance GW, Furlong W, Feeny D, Boyle M.

Pharmacoeconomics. 1995 Jun;7(6):503-20. Review.

PMID:
10155336
49.

Multi-attribute health status classification systems. Health Utilities Index.

Feeny D, Furlong W, Boyle M, Torrance GW.

Pharmacoeconomics. 1995 Jun;7(6):490-502. Review.

PMID:
10155335
50.

A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis.

Riedemann PJ, Bersinic S, Cuddy LJ, Torrance GW, Tugwell PX.

J Rheumatol. 1993 Dec;20(12):2095-103.

PMID:
8014938

Supplemental Content

Loading ...
Support Center